Chronic Idiopathic Urticaria Treatment Market Report 2026

The chronic idiopathic urticaria treatment market size has grown strongly in recent years. It will grow from $7.24 billion in 2025 to $7.89 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to increasing diagnosis of chronic urticaria, availability of second-line antihistamine therapies, adoption of stepwise treatment protocols, expansion of allergy specialty clinics, growing use of immunomodulatory drugs.

The chronic idiopathic urticaria treatment market size is expected to see strong growth in the next few years. It will grow to $11.23 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing demand for biologic treatment options, rising focus on personalized immunology care, expansion of digital disease management tools, growing investment in novel urticaria therapies, increasing patient awareness and treatment adherence. Major trends in the forecast period include increasing adoption of biologic therapies for refractory patients, growing use of personalized treatment pathways, rising integration of digital symptom monitoring tools, expansion of injectable treatment options, enhanced focus on long-term disease control.

The growing focus on biologic therapies is projected to strengthen the expansion of the chronic idiopathic urticaria treatment market in the coming years. Biologics are medical treatments developed from living organisms or their components that target specific immune system pathways to manage diseases. Interest in biologics is increasing due to advances in biotechnology and immunology that enable the creation of precise and highly effective therapies addressing underlying disease mechanisms rather than only symptoms. Biologic treatments act on immune pathways and mast cell activity responsible for chronic idiopathic urticaria, transforming treatment approaches and offering longer-lasting symptom relief. For example, in February 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, the 2023 Essential Medicines List included 81 biologic therapies, accounting for over 15% of all listed medicines. Therefore, the growing focus on biologics is supporting the growth of the chronic idiopathic urticaria treatment market.

Leading companies operating in the chronic idiopathic urticaria treatment market are emphasizing the development of innovative products, including monoclonal antibody therapies, to deliver targeted and long-lasting relief for patients who do not respond adequately to standard treatments. Monoclonal antibody therapies are biologic medications designed to specifically target immune components such as immunoglobulin E (IgE) or other inflammatory mediators responsible for chronic hives, providing more precise treatment compared with traditional antihistamines or corticosteroids. For example, in September 2025, Celltrion Inc., a South Korea-based biopharmaceutical company, launched Omriclo, an omalizumab biosimilar, in Norway. The product contains the same active monoclonal antibody as Xolair, works by neutralizing circulating IgE, and is administered through subcutaneous injection. Its distinguishing features include first-mover presence in Europe, expanded access via local distribution networks, and potential cost reductions for healthcare systems. It is designed for patients with chronic idiopathic urticaria who continue to experience symptoms despite standard therapies, offering improved symptom control, fewer flare-ups, and enhanced quality of life by reducing reliance on long-term antihistamine or corticosteroid use.

In March 2025, Novartis AG, a Switzerland-based pharmaceutical company, acquired global rights to the preclinical drug KRP-M223 from Kyorin Pharmaceutical Co. Ltd. for an upfront payment of $55 million. Through this agreement, Novartis plans to develop, manufacture, and commercialize KRP-M223, an MRGPRX2 antagonist intended to treat chronic spontaneous urticaria and other mast cell-related inflammatory disorders, while Kyorin retains rights to produce and sell the drug in Japan. Kyorin Pharmaceutical Co. Ltd. is a Japan-based pharmaceutical company focused on therapies for chronic idiopathic urticaria.

Major companies operating in the chronic idiopathic urticaria treatment market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG., AstraZeneca PLC, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Incyte Corporation, Dr. Reddy’s Laboratories Ltd., Celltrion Inc., Yuhan Corporation, Kiniksa Pharmaceuticals Ltd., Celldex Therapeutics Inc., Septerna Therapeutics Inc., Carna Biosciences Inc., United BioPharma Inc., Recludix Pharma Inc., Jasper Therapeutics Inc., Evommune Inc., ARS Pharmaceuticals Inc.

Tariffs are impacting the chronic idiopathic urticaria treatment market by increasing costs of imported biologic drugs, injectable delivery devices, pharmaceutical excipients, and specialized packaging materials. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported biologics, while Asia-Pacific faces pricing pressure on advanced therapy imports. These tariffs are increasing treatment costs and influencing reimbursement dynamics. However, they are also supporting local biologic manufacturing, regional formulation facilities, and long-term investment in domestic immunology drug development.

The chronic idiopathic urticaria treatment market research report is one of a series of new reports that provides chronic idiopathic urticaria treatment market statistics, including chronic idiopathic urticaria treatment industry global market size, regional shares, competitors with a chronic idiopathic urticaria treatment market share, detailed chronic idiopathic urticaria treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chronic idiopathic urticaria treatment industry. This chronic idiopathic urticaria treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic idiopathic urticaria treatment refers to the range of medical approaches used to manage persistent hives with no identifiable cause, focusing on relieving itching, swelling, and recurrent flare-ups while enhancing patient quality of life through effective symptom control. Management generally follows a stepwise strategy, beginning with non-sedating antihistamines, followed by increased dosing, additional biologic therapies, immunosuppressive agents, or short-term corticosteroid use in patients with moderate to severe or resistant symptoms.

The primary types of chronic idiopathic urticaria treatments include tablets, capsules, creams, lotions, and injections. Tablets are oral solid dosage forms used to alleviate symptoms associated with chronic urticaria. These treatments fall under drug classes such as antihistamines, corticosteroids, leukotriene receptor antagonists, immunosuppressants, biologic therapies, and other pharmaceutical classes. They are administered and distributed through oral, injectable, and topical routes via hospital pharmacies, retail pharmacies, and online pharmacies.

The chronic idiopathic urticaria treatment market includes revenues earned by entities through clinical diagnosis and disease assessment, allergy and trigger evaluation services, personalized treatment planning, antihistamine therapy management, and treatment response assessments. The market value includes the value of related digital tools and devices sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.